GCP
BNR

GSA Capital Partners’s Burning Rock Biotech BNR Stock Holding History

GSA Capital Partners’s Portfolio BNR Stock Details BNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,956
Closed -$118K – 1483
2022
Q3 		$118K Sell
4,956
-3,619
-42% -$117K 0.02% 1337
2022
Q2 		$250K Buy
+8,575
New +$383K 0.04% 936

Other funds holding BNR

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

GSA Capital Partners's BNR Position: Q4 2022 in Review

GSA Capital Partners sold out of Burning Rock Biotech (BNR) in Q4 2022, closing a stake of 4,956 shares — an estimated $118K sold.

GSA Capital Partners first reported a position in BNR in Q2 2022 and held it in 2 quarters. The position peaked at $250K in Q2 2022. 42 funds tracked by Wall St. Rank hold BNR as of Q4 2022.

  • GSA Capital Partners reported no remaining Burning Rock Biotech position as of Q4 2022 after selling out during the quarter.
  • GSA Capital Partners sold 4,956 Burning Rock Biotech shares in Q4 2022, an estimated $118K.
  • GSA Capital Partners first reported a position in Burning Rock Biotech in Q2 2022 and held it in 2 quarters.
  • GSA Capital Partners's Burning Rock Biotech position peaked at $250K in Q2 2022.
  • 42 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q4 2022.

Based on GSA Capital Partners's 13F filing for Q4 2022, filed 13 Feb 2023.